US 11,987,546 B2
Polycyclic carbogenic molecules and uses thereof as anti-cancer agents
Regan J. Thomson, Chicago, IL (US); and Emily E. Robinson, Chicago, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by Northwestern University, Evanston, IL (US)
Filed on Mar. 7, 2022, as Appl. No. 17/688,101.
Application 17/688,101 is a division of application No. 16/137,994, filed on Sep. 21, 2018, granted, now 11,286,226.
Claims priority of provisional application 62/561,464, filed on Sep. 21, 2017.
Prior Publication US 2022/0267241 A1, Aug. 25, 2022
Int. Cl. C07C 49/453 (2006.01); C07C 45/67 (2006.01); C07C 49/643 (2006.01); C07C 49/757 (2006.01); C07C 49/788 (2006.01); C07C 49/792 (2006.01); C07D 303/32 (2006.01); C07D 313/10 (2006.01)
CPC C07C 49/788 (2013.01) [C07C 45/673 (2013.01); C07C 49/453 (2013.01); C07C 49/643 (2013.01); C07C 49/757 (2013.01); C07C 49/792 (2013.01); C07D 303/32 (2013.01); C07D 313/10 (2013.01); C07B 2200/07 (2013.01); C07C 2603/26 (2017.05); C07C 2603/32 (2017.05); C07C 2603/36 (2017.05); C07C 2603/50 (2017.05); C07C 2603/94 (2017.05)] 17 Claims
 
1. A method for treating a cell proliferative disease or disorder in a subject in need thereof, the method comprising administering a pharmaceutical composition to the subject,
wherein the pharmaceutical composition comprises a compound having Formula I, or a salt, solvate, or epoxide thereof, and a pharmaceutical carrier:

OG Complex Work Unit Chemistry
wherein:
custom character is a single or double bond,
m and n are selected from 0 or 1; and
each occurrence of R1, R2, R3, R4, R5, R6, R7, and R8 is independently selected from hydrogen, alkyl, dialkyl, hydroxyl, protected hydroxyl, alkoxy, alkyl-alkoxy, alkyl-dialkoxy, and acetyl; or R3 and R5 together form an epoxide and R4 and R6 together from an epoxide; or R7 and R8 together from an epoxide.